

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GREATVIEW ASEPTIC PACKAGING COMPANY LIMITED

紛美包裝有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 00468)

QUARTERLY UPDATE ON THE STATUS OF RESUMPTION AND CONTINUED SUSPENSION OF TRADING

This announcement is made by Greatview Aseptic Packaging Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09 and 13.24A of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to: (i) the announcement made by the Company dated 19 February 2025 in relation to the suspension of trading in the shares of the Company; (ii) the announcement made by the Company dated 19 August 2025 in relation to resumption guidance and quarterly update on the status of resumption; (iii) the announcements made by the Company dated 31 December 2024, 20 January 2025, 28 February 2025, 17 April 2025 and 2 October 2025 (the “**October 2025 Announcement**”) in relation to, among other things, an independent investigation (the “**Special Investigation**”) concerning the transactions referred in the Company’s announcement dated 29 January 2024 (the “**Restructuring**”); and (iv) the announcements made by the Company dated 25 March 2025, 30 April 2025, 16 May 2025, 13 June 2025, 31 July 2025, 22 August 2025 and 27 October 2025 in relation to, among other things, the delay in publication of the Company’s annual results for the year ended 31 December 2024 (“**2024 Annual Results**”) and/or the interim results of the Group for the six months ended 30 June 2025 (“**2025 Interim Results**”) (collectively, the “**Announcements**”). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

QUARTERLY UPDATE

The Board wishes to update the Shareholders of, and potential investors in, the Company regarding the latest developments in relation to the Resumption Guidance.

Status of the Special Investigation

Reference is made to the October 2025 Announcement in relation to the final draft independent investigation report with regards to the Special Investigation (the “**Report**”) which was issued by the Investigator. Key findings of the Report and the Special Investigation have been announced in the October 2025 Announcement.

Since the conclusion of the Special Investigation, the Company has taken certain actions to address the internal control deficiencies within the Company which were identified in the Report. Such remedial actions are summarised as follows:

1. The Board has been informed by the Special Investigation Committee that it is finalising the scope for the second-stage independent investigation, with a view to investigate the relevant matters identified in the Report and to address certain regulatory concerns about the integrity, competence and/or character of the Group’s management as required in the Resumption Guidance. As at the date of this announcement, the Special Investigation Committee has not reached any definitive conclusions nor entered into any formal or legally binding agreement with any investigator with regards to the scope or timing of the second-stage investigation; and
2. The Board has appointed BT Corporate Governance Limited (the “**Internal Control Consultant**”) to undertake a thorough and extensive review of the Company’s internal control policies and mechanisms, with the aim to address any identified deficiencies as appropriate. As at the date of this announcement, the Internal Control Consultant is in the process of conducting the review. The Company will publish further announcement(s) on the progress of the review as and when appropriate.

Status of the preparation of the outstanding financial results

The Board has continued to engage in active discussions with the auditors of the Company and has also been working continuously to address any outstanding audit tasks and to complete the audit of the 2024 Annual Results as soon as possible. The Company is also in the process of collating the necessary information and documents and making progress in preparing the 2025 Interim Results. Further announcement(s) will be made by the Company to keep its shareholders and potential investors informed of developments as appropriate.

CONTINUED SUSPENSION OF TRADING

Trading in the shares of the Company has been suspended with effect from 9:00 a.m. on 19 February 2025 and will remain suspended until further notice.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Greatview Aseptic Packaging Company Limited
YUAN Xunjun
Chairman and Executive Director

Beijing, the People's Republic of China, 18 November 2025

As at the date of this announcement, the Board comprises two executive directors, namely, Mr. YUAN Xunjun and Mr. LEE Hsien Dar Victor; five non-executive directors, namely, Ms. WANG Ziting, Ms. WANG Yingli, Mr. CHOI Sum Shing Samson, Mr. YUEN Kai Yiu Kelvin and Mr. LI Weijin; and four independent non-executive directors, namely Ms. KOU Chung Yin Mariana, Mr. TANG Poon Tung Denny, Mr. CHOI Wai Hong Clifford and Mr. CHEN Qi.